Drug delivery strategies in the therapy of inflammatory bowel disease

被引:220
作者
Lautenschlaeger, Christian [1 ]
Schmidt, Carsten [1 ]
Fischer, Dagmar [2 ]
Stallmach, Andreas [1 ]
机构
[1] Univ Hosp Jena, Clin Internal Med 4, D-07740 Jena, Germany
[2] Univ Jena, Inst Pharm, Dept Pharmaceut Technol, D-07745 Jena, Germany
关键词
Inflammatory bowel disease; Drug targeting; Crohn's disease; Colitis ulcerosa; Targeted drug delivery; Particular drug delivery systems; Biological drug delivery systems; ACTIVE ULCERATIVE-COLITIS; COLON-SPECIFIC PRODRUG; LARGE POLYMERIC NANOPARTICLES; MODIFIED LACTOCOCCUS-LACTIS; INTESTINAL MUCUS BARRIER; DSS-INDUCED COLITIS; IN-VITRO EVALUATION; QUALITY-OF-LIFE; 5-AMINOSALICYLIC ACID; BACTERIAL GHOSTS;
D O I
10.1016/j.addr.2013.10.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inflammatory bowel disease (IBD) is a frequently occurring disease in young people, which is characterized by a chronic inflammation of the gastrointestinal tract. The therapy of IBD is dominated by the administration of anti-inflammatory and immunosuppressive drugs, which suppress the intestinal inflammatory burden and improve the disease-related symptoms. Established treatment strategies are characterized by a limited therapeutical efficacy and the occurrence of adverse drug reactions. Thus, the development of novel disease-targeted drug delivery strategies is intended for a more effective therapy and demonstrates the potential to address unmet medical needs. This review gives an overview about the established as well as future-oriented drug targeting strategies, including intestine targeting by conventional drug delivery systems (DDS), disease targeted drug delivery by synthetic DDS and disease targeted drug delivery by biological DDS. Furthermore, this review analyses the targeting mechanisms of the respective DDS and discusses the possible field of utilization in IBD. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:58 / 76
页数:19
相关论文
共 238 条
[91]   NANOSPHERE AND MICROSPHERE UPTAKE VIA PEYER PATCHES - OBSERVATION OF THE RATE OF UPTAKE IN THE RAT AFTER A SINGLE ORAL DOSE [J].
JANI, PU ;
MCCARTHY, DE ;
FLORENCE, AT .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 86 (2-3) :239-246
[92]   M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery [J].
Jepson, MA ;
Clark, MA ;
Hirst, BH .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (04) :511-525
[93]   Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes [J].
Jubeh, TT ;
Barenholz, Y ;
Rubinstein, A .
PHARMACEUTICAL RESEARCH, 2004, 21 (03) :447-453
[94]   Principles of adoptive T cell cancer therapy [J].
June, Carl H. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05) :1204-1212
[95]   Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? [J].
Jung, T ;
Kamm, W ;
Breitenbach, A ;
Kaiserling, E ;
Xiao, JX ;
Kissel, T .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) :147-160
[96]   Synthesis and properties of dextran-5-aminosalicylic acid ester as a potential colon-specific prodrug of 5-aminosalicylic acid [J].
Jung, YJ ;
Lee, JS ;
Kim, HH ;
Kim, YT ;
Kim, YM .
ARCHIVES OF PHARMACAL RESEARCH, 1998, 21 (02) :179-186
[97]   Synthesis and evaluation of 5-aminosalicyl-glycine as a potential colon-specific prodrug of 5-aminosalicylic acid [J].
Jung, YJ ;
Lee, JS ;
Kim, HH ;
Kim, YM ;
Han, SK .
ARCHIVES OF PHARMACAL RESEARCH, 1998, 21 (02) :174-178
[98]  
Jung YJ, 2000, J PHARM SCI-US, V89, P594, DOI 10.1002/(SICI)1520-6017(200005)89:5<594::AID-JPS5>3.0.CO
[99]  
2-8
[100]   New bilayer-coated microbead system for controlled release of 5-aminosalicylic acid [J].
Karewicz, Anna ;
Legowik, Joanna ;
Nowakowska, Maria .
POLYMER BULLETIN, 2011, 66 (03) :433-443